David R. Smith's most recent trade in Fortrea Holdings Inc was a trade of 38,817 Restricted Stock Unit done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fortrea Holdings Inc | David R. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 38,817 | 38,817 | - | - | Restricted Stock Unit | |
| Fortrea Holdings Inc | David R. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 7,282 | 0 | - | - | Restricted Stock Unit | |
| Fortrea Holdings Inc | David R. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 7,282 | 11,729 | - | 0 | Common Stock | |
| Fortrea Holdings Inc | David R. Smith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.78 per share. | 14 May 2025 | 2,185 | 9,544 | - | 4.8 | 10,444 | Common Stock |
| Fortrea Holdings Inc | David R. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 6,354 | 7,282 | - | - | Restricted Stock Unit | |
| Fortrea Holdings Inc | David R. Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 6,354 | 6,354 | - | 0 | Common Stock | |
| Fortrea Holdings Inc | David R. Smith | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.85 per share. | 18 Jul 2024 | 1,907 | 4,447 | - | 25.9 | 49,296 | Common Stock |
| Fortrea Holdings Inc | David R. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 7,282 | 13,636 | - | - | Restricted Stock Unit | |
| Fortrea Holdings Inc | David R. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 6,354 | 6,354 | - | - | Restricted Stock Unit | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 109.34 per share. | 03 Mar 2022 | 3,846 | 29,665 (0%) | 0% | 109.3 | 420,522 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 3,846 | 0 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 281.49 per share. | 03 Mar 2022 | 3,825 | 30,959 (0%) | 0% | 281.5 | 1,076,716 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 3,304 | 3,305 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 144.67 per share. | 03 Mar 2022 | 3,304 | 32,969 (0%) | 0% | 144.7 | 477,990 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 282.56 per share. | 03 Mar 2022 | 2,606 | 28,353 (0%) | 0% | 282.6 | 736,361 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 179.66 per share. | 03 Mar 2022 | 1,815 | 34,784 (0%) | 0% | 179.7 | 326,083 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2022 | 1,815 | 5,446 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 283.41 per share. | 03 Mar 2022 | 1,289 | 27,064 (0%) | 0% | 283.4 | 365,316 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 284.58 per share. | 03 Mar 2022 | 858 | 26,206 (0%) | 0% | 284.6 | 244,171 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 285.16 per share. | 03 Mar 2022 | 387 | 25,819 (0%) | 0% | 285.2 | 110,357 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 5,152 | 25,819 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.58 per share. | 22 Feb 2022 | 374 | 20,667 (0%) | 0% | 289.6 | 108,303 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 293.61 per share. | 22 Feb 2022 | 341 | 21,041 (0%) | 0% | 293.6 | 100,121 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 12,321 | 26,746 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 312.24 per share. | 28 Jan 2022 | 5,364 | 21,382 (0%) | 0% | 312.2 | 1,674,855 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 407.95 per share. | 09 Aug 2021 | 1,150 | 14,425 (0%) | 0% | 407.9 | 469,139 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 406.36 per share. | 09 Aug 2021 | 600 | 15,575 (0%) | 0% | 406.4 | 243,815 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 4,058 | 4,058 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 1,313 | 16,175 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2021 | 3,305 | 6,609 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 340.01 per share. | 04 May 2021 | 3,305 | 14,862 (0%) | 0% | 340.0 | 1,123,718 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 144.67 per share. | 04 May 2021 | 3,305 | 18,167 (0%) | 0% | 144.7 | 478,134 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 109.34 per share. | 22 Apr 2021 | 3,845 | 18,707 (0%) | 0% | 109.3 | 420,412 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 330.00 per share. | 22 Apr 2021 | 3,845 | 14,862 (0%) | 0% | 330 | 1,268,850 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2021 | 3,845 | 3,846 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 320.00 per share. | 15 Apr 2021 | 2,000 | 14,862 (0%) | 0% | 320 | 640,000 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 4,366 | 0 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 290.12 per share. | 01 Mar 2021 | 4,366 | 16,862 (0%) | 0% | 290.1 | 1,266,647 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.05 per share. | 01 Mar 2021 | 4,366 | 21,228 (0%) | 0% | 88.0 | 384,426 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 282.98 per share. | 24 Feb 2021 | 289 | 16,862 (0%) | 0% | 283.0 | 81,781 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.59 per share. | 22 Feb 2021 | 242 | 17,151 (0%) | 0% | 283.6 | 68,629 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.55 per share. | 22 Feb 2021 | 157 | 17,393 (0%) | 0% | 289.5 | 45,459 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 14,234 | 21,345 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Jan 2021 | 8,656 | 8,656 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Jan 2021 | 8,656 | 7,111 (0%) | 0% | 0 | Common Stock | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 260.88 per share. | 25 Jan 2021 | 3,795 | 17,550 (0%) | 0% | 260.9 | 990,040 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 248.84 per share. | 04 Jan 2021 | 935 | 17,581 (0%) | 0% | 248.8 | 232,662 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 247.89 per share. | 04 Jan 2021 | 756 | 18,516 (0%) | 0% | 247.9 | 187,406 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 246.76 per share. | 04 Jan 2021 | 535 | 19,272 (0%) | 0% | 246.8 | 132,017 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 249.97 per share. | 04 Jan 2021 | 531 | 17,050 (0%) | 0% | 250.0 | 132,734 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 243.71 per share. | 04 Jan 2021 | 531 | 20,236 (0%) | 0% | 243.7 | 129,408 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 251.90 per share. | 04 Jan 2021 | 426 | 16,491 (0%) | 0% | 251.9 | 107,311 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 253.88 per share. | 04 Jan 2021 | 310 | 15,878 (0%) | 0% | 253.9 | 78,704 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 252.99 per share. | 04 Jan 2021 | 303 | 16,188 (0%) | 0% | 253.0 | 76,656 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 245.57 per share. | 04 Jan 2021 | 264 | 19,807 (0%) | 0% | 245.6 | 64,830 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 244.95 per share. | 04 Jan 2021 | 165 | 20,071 (0%) | 0% | 244.9 | 40,416 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 250.86 per share. | 04 Jan 2021 | 133 | 16,917 (0%) | 0% | 250.9 | 33,365 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 254.77 per share. | 04 Jan 2021 | 111 | 15,767 (0%) | 0% | 254.8 | 28,280 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2020 | 3,304 | 9,914 | - | - | Stock Options (Right to Buy) | |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 144.67 per share. | 07 Aug 2020 | 3,304 | 24,071 (0%) | 0% | 144.7 | 477,990 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 216.42 per share. | 07 Aug 2020 | 2,297 | 21,774 (0%) | 0% | 216.4 | 497,110 | Common Stock |
| Charles River Laboratories... | David R. Smith | Corporate Executive VP & CFO | Sale of securities on an exchange or to another person at price $ 216.82 per share. | 07 Aug 2020 | 1,007 | 20,767 (0%) | 0% | 216.8 | 218,334 | Common Stock |